These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35545234)

  • 61. Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity.
    de Araujo M; Seguro AC
    Antivir Ther; 2002 Sep; 7(3):181-4. PubMed ID: 12487385
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum and saliva concentrations of sulfamethoxazole and trimethoprim in adults and children: relation between saliva concentrations and in vitro activity against nasopharyngeal pathogens.
    Kamme C; Melander A; Nilsson NI
    Scand J Infect Dis; 1983; 15(1):107-13. PubMed ID: 6342125
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
    Wordell CJ; Hauptman SP
    Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Does Trimethoprim-Sulfamethoxazole prophylaxis induce myelosuppression in primary immune deficiency disease patients; A retrospective, 3 groups comparative study.
    Elajez R; Nisar S; Adeli M
    Asian Pac J Allergy Immunol; 2023 Dec; 41(4):353-360. PubMed ID: 33068365
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients.
    Skoloda D; Newman M; Norman H; Ziggas JE; Ambinder RF
    JCO Oncol Pract; 2024 May; 20(5):673-677. PubMed ID: 38382007
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
    Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology.
    Kokubu H; Kato T; Nishikawa J; Tanaka T; Fujimoto N
    J Dermatol; 2021 Apr; 48(4):542-546. PubMed ID: 33492693
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
    Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
    Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
    Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
    PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source.
    Sutton JD; Stevens VW; Chang NN; Khader K; Timbrook TT; Spivak ES
    JAMA Netw Open; 2020 Oct; 3(10):e2020166. PubMed ID: 33030555
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.
    Creemers-Schild D; Kroon FP; Kuijper EJ; de Boer MG
    Infection; 2016 Jun; 44(3):291-9. PubMed ID: 26471512
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy.
    Kesner JM; Yardman-Frank JM; Mercier RC; Wong CS; Walker SE; Argyres DP; Vilay AM
    Blood Purif; 2014; 38(3-4):195-202. PubMed ID: 25531772
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs.
    Mengelers MJ; Van Gogh ER; Kuiper HA; Pijpers A; Verheijden JH; Van Miert AS
    J Vet Pharmacol Ther; 1995 Aug; 18(4):243-53. PubMed ID: 8583537
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas.
    Chakwenya J; Lakritz J; Tyler J; Fales WH; James-Kracke M; Smith K; Holle J
    J Vet Pharmacol Ther; 2002 Oct; 25(5):321-7. PubMed ID: 12423221
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Emergence of highly trimethoprim-sulfamethoxazole-resistant Shigella in a native American population: an epidemiologic study.
    Griffin PM; Tauxe RV; Redd SC; Puhr ND; Hargrett-Bean N; Blake PA
    Am J Epidemiol; 1989 May; 129(5):1042-51. PubMed ID: 2650535
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients.
    Plantaz MMEA; Veldman BAJ; Esselink AC; Fleuren HWHA; Kramers C
    Int J Clin Pharm; 2020 Dec; 42(6):1405-1411. PubMed ID: 33025449
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole.
    Perlmutter EP; Sweeney D; Herskovits G; Kleiner M
    Am J Med Sci; 1996 Feb; 311(2):84-5. PubMed ID: 8615380
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter Inhibition.
    Nakada T; Kudo T; Ito K
    Drug Metab Dispos; 2023 Sep; 51(9):1114-1126. PubMed ID: 36859345
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
    Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
    Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.